# Roflumilast as add-on Therapy in Early Cases of ARDS

> **NCT04744090** · PHASE2 · COMPLETED · sponsor: **Cairo University** · enrollment: 76 (actual)

## Conditions studied

- Respiratory Distress Syndrome, Adult

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04744090
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-21
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-01-01
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04744090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04744090, "Roflumilast as add-on Therapy in Early Cases of ARDS". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04744090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*